The estimated Net Worth of Richard Klausner is at least $96.7 Milión dollars as of 5 January 2018. Richard Klausner owns over 12,724 units of Illumina Inc stock worth over $90,972,983 and over the last 11 years Richard sold ILMN stock worth over $5,761,113.
Richard has made over 11 trades of the Illumina Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Richard sold 12,724 units of ILMN stock worth $613,424 on 5 January 2018.
The largest trade Richard's ever made was selling 36,000 units of Illumina Inc stock on 21 December 2017 worth over $1,611,360. On average, Richard trades about 5,656 units every 40 days since 2014. As of 5 January 2018 Richard still owns at least 728,775 units of Illumina Inc stock.
You can see the complete history of Richard Klausner stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley a Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: